Abstract
While it is well established that host heterogeneity in transmission and host heterogeneity in susceptibility each individually impact disease dynamics in characteristic ways, it is generally unknown how disease dynamics are impacted when both types of heterogeneity are simultaneously present. Here we explore this question. We first conducted a systematic review of published studies from which we determined that the effects of correlations have been drastically understudied. We then filled in the knowledge gaps by developing and analyzing a stochastic, individual-based SIR model that includes both heterogeneity in transmission and susceptibility and flexibly allows for positive or negative correlations between transmissibility and susceptibility. We found that in comparison to the uncorrelated case, positive correlations result in major epidemics that are larger, faster, and more likely, whereas negative correlations result in major epidemics that are smaller and less likely. We additionally found that, counter to the conventional wisdom that heterogeneity in susceptibility always reduces outbreak size, heterogeneity in susceptibility can lead to major epidemics that are larger and more likely than the homogeneous case when correlations between transmissibility and susceptibility are positive, but this effect only arises at small to moderate R0. Moreover, positive correlations can frequently lead to major epidemics with subcritical R0. Ultimately, we show that correlations between transmissibility and susceptibility profoundly impact disease dynamics.
Highlights
Systematic review finds that effects of correlations on epidemics are understudied
Positive correlations lead to larger, faster, more likely epidemics
Negative correlations lead to smaller, less likely epidemics
Positive correlations consistently lead to major epidemics with subcritical R0
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
DAK and BMT were supported by Institute of General Medical Sciences, National Institutes of Health (R01GM140459) and the UK Biotechnology and Biological Sciences Research Council as part of the joint NSF-NIH-USDA Ecology and Evolution of Infectious Diseases program. DAK was also supported by National Science Foundation grant DEB-2211322. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of this article.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos